heptakis(2,6-o-dimethyl)beta-cyclodextrin and Alzheimer Disease

heptakis(2,6-o-dimethyl)beta-cyclodextrin has been researched along with Alzheimer Disease in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Değim, Z; Eşsiz, D; Mutlu, NB; Nacar, A; Yilmaz, Ş	1

Other Studies

1 other study(ies) available for heptakis(2,6-o-dimethyl)beta-cyclodextrin and Alzheimer Disease

Article	Year
New perspective for the treatment of Alzheimer diseases: liposomal rivastigmine formulations. Drug development and industrial pharmacy, 2011, Volume: 37, Issue:7 Topics: Alzheimer Disease; Animals; beta-Cyclodextrins; Biological Availability; Brain; Cell Line; Cholinesterase Inhibitors; Dogs; Drug Carriers; Drug Compounding; Drug Delivery Systems; Drug Stability; Humans; Liposomes; Male; Mice; Mice, Inbred BALB C; Microscopy, Electron, Transmission; Neuroprotective Agents; Particle Size; Phenylcarbamates; Rivastigmine; Taurocholic Acid	2011

Article

Year

New perspective for the treatment of Alzheimer diseases: liposomal rivastigmine formulations.

Drug development and industrial pharmacy, 2011, Volume: 37, Issue:7

Topics: Alzheimer Disease; Animals; beta-Cyclodextrins; Biological Availability; Brain; Cell Line; Cholinesterase Inhibitors; Dogs; Drug Carriers; Drug Compounding; Drug Delivery Systems; Drug Stability; Humans; Liposomes; Male; Mice; Mice, Inbred BALB C; Microscopy, Electron, Transmission; Neuroprotective Agents; Particle Size; Phenylcarbamates; Rivastigmine; Taurocholic Acid

2011